Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatorymediated diseases Eli Lilly

Ventyx’s clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly’s established capabilities in inflammatory… [+12888 chars]Read More